1. Home
  2. BCML vs PLYX Comparison

BCML vs PLYX Comparison

Compare BCML & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayCom Corp

BCML

BayCom Corp

HOLD

Current Price

$30.40

Market Cap

338.6M

Sector

Finance

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$3.44

Market Cap

271.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCML
PLYX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.6M
271.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BCML
PLYX
Price
$30.40
$3.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$34.00
$10.00
AVG Volume (30 Days)
37.3K
108.5K
Earning Date
04-23-2026
05-22-2026
Dividend Yield
4.09%
N/A
EPS Growth
3.81
N/A
EPS
0.75
N/A
Revenue
N/A
N/A
Revenue This Year
$13.71
N/A
Revenue Next Year
$5.25
N/A
P/E Ratio
$40.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.06
$2.20
52 Week High
$33.15
$9.18

Technical Indicators

Market Signals
Indicator
BCML
PLYX
Relative Strength Index (RSI) 57.28 35.36
Support Level $27.23 $2.58
Resistance Level $30.74 $7.29
Average True Range (ATR) 0.63 0.54
MACD 0.11 -0.19
Stochastic Oscillator 66.74 19.78

Price Performance

Historical Comparison
BCML
PLYX

About BCML BayCom Corp

BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses, and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services. The Company operates as one reportable segment: banking operations.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: